FBIO
Fortress Biotech Inc Pref Series A
NASDAQ: FBIOP · HEALTHCARE · BIOTECHNOLOGY
$18.37
-1.10% today
Updated 2026-09-11
Market cap
$77.81M
P/E ratio
—
P/S ratio
1.23x
EPS (TTM)
$-0.86
Dividend yield
—
52W range
$6 – $21
Volume
0.0M
WallStSmart proprietary scores
44
out of 100
Grade: D
Sell
Investment rating
4.0
Growth
C6.5
Quality
B6.0
Profitability
B6.0
Valuation
B4/9
Piotroski F-Score
Moderate
-4.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
$13.38
Margin of safety
+15.47%
Price chart
Stock snapshot
Strengths
+ Profit margin 163.30% — above average
+ ROE 78.77% — strong efficiency
+ Revenue growth 14.00% QoQ
+ 15.47% below intrinsic value
+ Debt/equity 0.39x — low leverage
Risks
- Altman Z -4.86 — distress zone
- Negative free cash flow $-59.36M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $75.74M | $84.51M | $57.67M | $63.26M | $68.47M |
| Net income | $-86.58M | $-60.64M | $-46.00M | $6.82M | $-468000.00 |
| EPS | — | — | — | — | $-0.86 |
| Free cash flow | $-182.46M | $-136.32M | $-95.19M | $-65.78M | $-59.36M |
| Profit margin | -114.30% | -71.75% | -79.75% | 10.77% | 163.30% |
Peer comparison
Smart narrative
Fortress Biotech Inc Pref Series A trades at $18.37. Our Smart Value Score of 44/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -4.86, it sits in the distress. TTM revenue stands at $68.47M. with profit margins at 163.30%. Our DCF model estimates intrinsic value at $13.38.
Frequently asked questions
What is Fortress Biotech Inc Pref Series A's stock price?
Fortress Biotech Inc Pref Series A (FBIOP) trades at $18.37, on a P/S of 1.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Fortress Biotech Inc Pref Series A overvalued?
Fortress Biotech Inc Pref Series A carries a Smart Value Score of 44/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $13.38 versus the $18.37 price, a 15.5% margin of safety on a cash flow basis.
What is the intrinsic value of Fortress Biotech Inc Pref Series A (FBIOP)?
Our DCF model estimates intrinsic value at $13.38, a +15.5% margin of safety versus today's $18.37. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Fortress Biotech Inc Pref Series A's revenue?
Fortress Biotech Inc Pref Series A's trailing twelve-month revenue is $68.47M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Fortress Biotech Inc Pref Series A's Altman Z-Score is -4.86, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.23x
ROE78.77%
Beta1.21
50D MA$19.06
200D MA$14.41
Shares out0.06B
Float0.02B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—